Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Multi-dimensional factors of behavioral intention of COVID-19 booster vaccination among people having contracted COVID-19-a 7-city study conducted during the last national major outbreak in China.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100968562 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2458 (Electronic) Linking ISSN: 14712458 NLM ISO Abbreviation: BMC Public Health Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: London : BioMed Central, [2001-
    • الموضوع:
    • نبذة مختصرة :
      Introduction: The COVID-19 reinfection rate is high, and COVID-19 remains a significant public health threat. Booster vaccination is effective in reducing reinfection and the severity of infection. To increase the booster vaccination rate among people having contracted COVID-19 (PCC), it is warranted to understand the prevalence and factors of behavioral intention to take up COVID-19 booster vaccination. Multi-dimensional factors, including cognitive factors (cognitive factors of illness representation (IR) and perceived inevitability of infection), emotional factors (emotional factors of IR and panic), psychosocial factors (depressive symptoms and social support), and a behavioral factor (social distancing behavior), were examined for their association with behavioral intention to take up COVID-19 booster vaccination after six months since the COVID-19 diagnosis (BI-BCV).
      Methods: An anonymous cross-sectional online survey was conducted among the adult PCC population in seven cities located in eastern, southern, western, northern, and north-western China using stratified clustered sampling from December 27, 2022 through January 9, 2023, which is during China's last national major outbreak.
      Results: A total of 5,757 PCC were included in the study. The prevalence of BI-BCV was 65.8%. Age, employment status, community type (rural/urban), chronic disease control status, marital status, education level, infection timing, and city were significantly associated with BI-BCV. The multivariate logistic regression yielded that IR constructs of treatment control, IR of illness coherence, social support, and social distancing behavior factors were positively associated with BI-BCV. In addition, IR of perceived consequences of COVID-19, perceived inevitability of infection, and depressive symptoms were negatively associated with BI-BCV. The emotional factors (panic and emotional IR) were non-significant.
      Conclusions: The BI-BCV prevalence was lower than ideal and warrants health promotion. We found that some cognitions (IR constructs of illness coherence, treatment control, and perceived consequences of COVID-19 and perceived inevitability of infection), behavior (social distancing), psychosocial factors (depression and social support), but not emotional states related to COVID-19, were potential determinants of BI-BCV. Future longitudinal studies are warranted to confirm the findings. Health workers may consider modifications of the significant factors found in this study.
      (© 2025. The Author(s).)
    • نبذة مختصرة :
      Declarations. Ethics approval and consent to participate: Ethics approval was obtained from the ethics committee of School of Public Health, Zhejiang University (No. ZLG202301-01). Informed consent was obtained from all subjects involved in this study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
    • References:
      N Engl J Med. 2022 Mar 31;386(13):1221-1229. (PMID: 35172072)
      Fam Process. 2021 Sep;60(3):1002-1015. (PMID: 33220082)
      J Anxiety Disord. 2020 Oct;75:102291. (PMID: 32827869)
      Curr Psychol. 2023;42(8):6447-6456. (PMID: 34155427)
      Appl Psychol Health Well Being. 2020 Dec;12(4):967-982. (PMID: 33016617)
      Gen Hosp Psychiatry. 2014 Sep-Oct;36(5):539-44. (PMID: 25023953)
      Front Psychol. 2021 Jul 12;12:674018. (PMID: 34322062)
      Int J Psychol. 2014 Apr;49(2):63-70. (PMID: 24811876)
      Vaccine. 2024 Jan 12;42(2):206-212. (PMID: 38065769)
      Vaccines (Basel). 2022 Dec 25;11(1):. (PMID: 36679890)
      BMJ Open. 2022 Apr 11;12(4):e053938. (PMID: 35410924)
      China CDC Wkly. 2021 Jun 18;3(25):531-537. (PMID: 34594928)
      Psychiatry Res. 2022 Jan;307:114329. (PMID: 34910966)
      Curr Med Res Pract. 2020 Mar-Apr;10(2):78-79. (PMID: 32292804)
      AIDS Behav. 2017 Jan;21(1):261-273. (PMID: 26896120)
      J Epidemiol Community Health. 2022 Feb;76(2):109-115. (PMID: 34244309)
      MMWR Morb Mortal Wkly Rep. 2023 Jun 23;72(25):683-689. (PMID: 37347715)
      PLoS One. 2021 Feb 16;16(2):e0246970. (PMID: 33592035)
      Hum Vaccin Immunother. 2020 Sep 1;16(9):2204-2214. (PMID: 32730103)
      F1000Res. 2020 Jun 23;9:636. (PMID: 33093946)
      Int J Environ Res Public Health. 2021 May 30;18(11):. (PMID: 34070713)
      Epidemiol Psichiatr Soc. 2008 Jan-Mar;17(1):31-7. (PMID: 18444456)
      Front Public Health. 2023 Sep 04;11:1158096. (PMID: 37727606)
      J Psychol. 1975 Sep;91(1):93-114. (PMID: 28136248)
      J Health Psychol. 2015 Dec;20(12):1523-33. (PMID: 24423574)
      Int J Surg. 2020 Jun;78:185-193. (PMID: 32305533)
      Health Psychol. 2001 May;20(3):223-7. (PMID: 11403220)
      Pharm Pract (Granada). 2021 Jan-Mar;19(1):2317. (PMID: 33828623)
      Expert Rev Vaccines. 2022 Mar;21(3):385-395. (PMID: 34974779)
      J Psychosom Res. 1996 Aug;41(2):171-80. (PMID: 8887830)
      PLoS One. 2017 Mar 20;12(3):e0174093. (PMID: 28319160)
      J Psychosom Res. 2009 Jul;67(1):17-23. (PMID: 19539814)
      Patient Educ Couns. 2022 Feb;105(2):277-283. (PMID: 34565643)
      Vaccines (Basel). 2021 Aug 24;9(9):. (PMID: 34579178)
      JAMA Intern Med. 2020 Jul 1;180(7):1020-1022. (PMID: 32259192)
      PLOS Glob Public Health. 2022 Dec 28;2(12):e0001435. (PMID: 36962915)
      Inj Prev. 2000 Jun;6(2):82-90. (PMID: 10875661)
      Pharm Pract (Granada). 2022 Oct-Dec;20(4):2748. (PMID: 36793907)
      J Med Internet Res. 2020 Dec 31;22(12):e23729. (PMID: 33293262)
      J Adv Nurs. 2016 Jul;72(7):1469-89. (PMID: 26781649)
      Front Immunol. 2021 Nov 29;12:781161. (PMID: 34912346)
      Travel Med Infect Dis. 2021 May-Jun;41:102059. (PMID: 33848692)
      Eur J Public Health. 2010 Oct;20(5):490-4. (PMID: 20444821)
      N Engl J Med. 2022 Mar 31;386(13):1207-1220. (PMID: 35172051)
      Int J Health Policy Manag. 2022 Jul 1;11(7):1090-1101. (PMID: 33619928)
      Curr Psychol. 2022;41(1):492-504. (PMID: 33846675)
      Trop Med Infect Dis. 2022 Oct 13;7(10):. (PMID: 36288039)
      Biomed Res Int. 2022 Jan 6;2022:3401566. (PMID: 35005026)
      PLoS Med. 2020 Jul 21;17(7):e1003166. (PMID: 32692736)
      Vaccines (Basel). 2022 Oct 11;10(10):. (PMID: 36298562)
      Transl Behav Med. 2021 May 25;11(5):1179-1186. (PMID: 33598679)
      Eur J Clin Invest. 2022 Oct;52(10):e13845. (PMID: 35904405)
      Sci Rep. 2021 Jan 28;11(1):2601. (PMID: 33510195)
      Vaccines (Basel). 2021 Apr 13;9(4):. (PMID: 33924604)
      Lancet. 2021 Nov 6;398(10312):1700-1712. (PMID: 34634250)
      J Multidiscip Healthc. 2020 Nov 20;13:1657-1663. (PMID: 33262600)
      Healthcare (Basel). 2022 Sep 24;10(10):. (PMID: 36292305)
      J Health Psychol. 2022 Jul;27(8):1846-1860. (PMID: 33878946)
      BMC Geriatr. 2022 Apr 6;22(1):288. (PMID: 35387602)
      Prev Med. 2022 Jan;154:106905. (PMID: 34863815)
      BMC Psychiatry. 2021 Jan 7;21(1):16. (PMID: 33413238)
      Int J Environ Res Public Health. 2022 Jul 28;19(15):. (PMID: 35954625)
      Wellcome Open Res. 2020 Apr 28;5:81. (PMID: 32500100)
      Hum Vaccin Immunother. 2021 May 4;17(5):1455-1462. (PMID: 32991245)
      J Med Virol. 2022 May;94(5):1761-1765. (PMID: 35014038)
      Sci Rep. 2024 Jun 20;14(1):14244. (PMID: 38902279)
      J Anxiety Disord. 2020 Aug;74:102258. (PMID: 32569905)
      Nat Med. 2022 Nov;28(11):2398-2405. (PMID: 36357676)
      Vaccines (Basel). 2022 Jun 18;10(6):. (PMID: 35746581)
      Eur J Investig Health Psychol Educ. 2022 Aug 15;12(8):1121-1142. (PMID: 36005228)
      BMC Infect Dis. 2021 Aug 31;21(1):892. (PMID: 34465297)
      Health Educ Q. 1984 Spring;11(1):1-47. (PMID: 6392204)
      Healthcare (Basel). 2023 Aug 29;11(17):. (PMID: 37685451)
      Lancet. 2020 Mar 14;395(10227):912-920. (PMID: 32112714)
      Soc Sci Med. 2023 Mar;320:115695. (PMID: 36736053)
      Pain Physician. 2020 Aug;23(4S):S367-S380. (PMID: 32942794)
      J Gen Intern Med. 2001 Sep;16(9):606-13. (PMID: 11556941)
      Heliyon. 2023 Aug 11;9(8):e19090. (PMID: 37636345)
      J Med Internet Res. 2021 Mar 9;23(3):e24673. (PMID: 33646966)
      Vaccine. 2021 Jan 8;39(2):247-254. (PMID: 33328140)
      Math Comput Simul. 2022 Oct;200:285-314. (PMID: 35531464)
      Psychiatry Res. 2020 Nov;293:113462. (PMID: 32987222)
      J Community Health. 2022 Aug;47(4):627-634. (PMID: 35451692)
      Hum Vaccin Immunother. 2022 Nov 30;18(5):2078634. (PMID: 35648441)
      J Med Internet Res. 2020 Sep 4;22(9):e22227. (PMID: 32886066)
    • Contributed Indexing:
      Keywords: Booster vaccination; COVID-19; China; Cognitive factors; Depression; Emotional factors; Illness representation; Social distancing; Social support
    • الرقم المعرف:
      0 (COVID-19 Vaccines)
    • الموضوع:
      Date Created: 20251230 Date Completed: 20251231 Latest Revision: 20260102
    • الموضوع:
      20260102
    • الرقم المعرف:
      PMC12754956
    • الرقم المعرف:
      10.1186/s12889-025-23915-6
    • الرقم المعرف:
      41469869